Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Predictors of Diagnosis and Outcome in Pediatric MOG-antibody Associated Disorders
Multiple Sclerosis
P14 - Poster Session 14 (8:00 AM-9:00 AM)
9-006
To characterize a cohort of MOG-positive (MOG+) patients at our pediatric tertiary care institution and identify clinical, laboratory, and radiographic predictors of diagnosis and treatment response in MOG+ patients. 
Antibodies to Myelin Oligodendrocyte Glycoprotein (MOG) are found in about one-third of children with an acquired demyelinating syndrome (ADS).  Little is known about which clinico-radiographic and laboratory determinants predict a diagnosis of a MOG-related disorder and response to treatment.
We retrospectively reviewed records of patients between the ages of 0-18 followed at the Children’s Hospital of Philadelphia with MOG-antibody testing performed between January 1, 2014 and January 1, 2019.  Logistic regression modeling was used to identify clinico-radiographic determinants associated with a MOG-related disorder diagnosis and response to treatment.
Of the 21 MOG+ patients, 13 (61.9%) were female and the median age was 7 (3-17) years. The most common presenting phenotype was ADEM (38.1%).  An abnormal brain MRI at presentation was found in 19 of the 21 MOG+ patients (90.5%) with the most common findings being cerebral white matter lesions (73.7%) and deep gray matter involvement (68.4%).  9 out of 17 MOG+ patients had abnormal spinal imaging (52.9%) with longitudinally extensive lesions being the most common finding (77.8%).  Oligoclonal bands (OCBs) occurred in a subset of MOG+ patients (31.2%). Clinical relapses occurred in 12 of the 21 MOG+ children (57.1%) and these patients were universally treated with disease modifying therapies (DMTs). 
MOG-related disorders present with a wide spectrum of phenotypes with ADEM being the most common in our cohort. Cerebral white matter lesions, deep gray matter involvement, and longitudinally extensive cord lesions were common in MOG+ children. OCBs in CSF occur in a subset of MOG+ children. Treatment with DMTs was utilized in all children with a relapsing course leading to cessation in relapses in the majority.
Authors/Disclosures
Duriel I. Hardy, MD (Dell Children's Specialty Pavillian)
PRESENTER 		Dr. Hardy has nothing to disclose.
Jennifer McGuire, MD (Children's Hospital of Philadelphia) Dr. McGuire has received research support from NIH.
Brenda L. Banwell, MD, FÂ鶹´«Ã½Ó³»­ (Johns Hopkins University) Dr. Banwell has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Banwell has received personal compensation in the range of $0-$499 for serving as a Consultant for UCB. Dr. Banwell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Banwell has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Banwell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Banwell has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. Banwell has received research support from National MS Society. The institution of Dr. Banwell has received research support from NIH.
Sarah E. Hopkins, MD (The Children'S Hospital of Philadelphia) The institution of Dr. Hopkins has received research support from NIH. The institution of Dr. Hopkins has received research support from CDC.